SEC Comment Letter 0000000000-22-013452 to Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635)
Date: Dec. 14, 2022 · CIK: 0001829635 · Accession: 0000000000-22-013452
AI Filing Summary & Sentiment
File numbers found in text: 333-268764
Letter
United States securities and exchange commission logo December 14, 2022 R. Michael Dudley Chief Executive Officer Transcode Therapeutics, Inc. 6 Liberty Square — #2382 Boston, MA 02109 Re:Transcode Therapeutics, Inc. Registration Statement on Form S-3 Filed December 13, 2022 File No. 333-268764 Dear R. Michael Dudley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finnbarr Murphy, Esq.
Show Raw Text
United States securities and exchange commission logo
December 14, 2022
R. Michael Dudley
Chief Executive Officer
Transcode Therapeutics, Inc.
6 Liberty Square — #2382
Boston, MA 02109
Re:Transcode Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 13, 2022
File No. 333-268764
Dear R. Michael Dudley:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Finnbarr Murphy, Esq.